eviplera
J - Antiinfectives For Systemic Use -> J05 - Antivirals For Systemic Use -> J05A - Direct Acting Antivirals -> J05AR - Combinations -> J05AR08 - Eviplera
Administration category:
Free
Medicine group:
antiviral
Brand name:
Eviplera
Standard dosages
| Weight | ROA | Load | Dosage |
|---|---|---|---|
|
ROA: po |
Load: - |
Dosage: 1pieces 1 dd |
Kidney function
| ROA | GFR | Dosage | Interval | Comments |
|---|---|---|---|---|
| ROA: po | ||||
|
GFR: 30 - 50 |
Dosage: do not prescribe |
|||
|
GFR: <30 |
Dosage: do not prescribe |
|||
Renal elimination:
tenofovir: 70-80%, emtricitabine: 86%, rilpivirine: 6%
Dosage:
dependent on kidney function
Renal function-replacement therapy
CAPD: vermijd gebruik van het combinatiepreparaat
Hemo dialysis: vermijd gebruik van het combinatiepreparaat
CAV / VVHD: vermijd gebruik van het combinatiepreparaat
Pregnancy
Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Zwangerschap#TOC_Middelen_bij6
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Borstvoeding#TOC_Middelen_bij16
For individual advice, consult an expert on site.
Metadata
Swab vid: M-2964.2
Updated: 06/16/2019 - 20:05
Status: Published
General comments
1 tablet 1 dd p.o.: bevat tenofovirdisoproxil (als fumaraat) 245 mg, emtricitabine 200 mg, rilpivirine (als hydrochloride) 25 mg